Viral hepatitis in solid organ transplant recipients

American Journal of Transplantation

Volumn 9, Issue SUPPL. 4, 2009, Pages

  Levitsky, J ^a   Doucette, K ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Hepatitis B immunoglobulin; Hepatitis B virus; Hepatitis C virus; Interferon; Nucleos(t)ide analogues

Indexed keywords

ADEFOVIR; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; RAPAMYCIN; RIBAVIRIN; STEROID; TACROLIMUS; TELBIVUDINE; VIRUS DNA; VIRUS RNA;

ACUTE GRAFT REJECTION; ADJUVANT THERAPY; ANTIVIRAL THERAPY; COMBINATION CHEMOTHERAPY; DNA VIRUS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; RNA VIRUS; TREATMENT RESPONSE; VIRUS HEPATITIS; VIRUS LOAD;

HEPATITIS B; HEPATITIS C; HUMANS; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 72949093377     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02902.x     Document Type: Review

References (225)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997 337 : 1733 1745.
2. Poland GA, Jacobson RM. Clinical practice: Prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004 351 : 2832 2838.
3. Cohen C, Evans AA, London WT et al. Underestimation of chronic hepatitis B virus infection in the United States of America. J Viral Hep 2008 15 : 12 13.
4. Kapoor D, Guptan RC, Wakil SM et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000 33 : 308 312.
5. Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001 33 : 424 432.
6. Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000 31 : 207 210.
7. Yao FY, Terrault NA, Freise C et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology 2001 34 : 411 416.
8. Todo S, Demetris AJ, Van Thiel D et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991 13 : 619 626.
9. O'Grady JG, Smith HM, Davies SE et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992 14 : 104 111.
10. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation (2). N Engl J Med 1989 321 : 1092 1099.
11. Vierling JM, Teperman LW. Introduction to hepatitis B transplantation. Semin Liver Dis 2000 20 : 1 2.
12. Brind A, Jiang J, Samuel D et al. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J Hepatol 1997 26 : 228 235.
13. Feray C, Zignego AL, Samuel D et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990 49 : 1155 1158.
14. Mazet-Wagner AA, Baclet MC, Loustaud-Ratti V et al. Real-time PCR quantitation of hepatitis B virus total DNA and covalently closed circular DNA in peripheral blood mononuclear cells from hepatitis B virus-infected patients. J Virol Methods 2006 138 : 70 79.
15. Buti M, Mas A, Prieto M et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003 38 : 811 817.
16. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hep 2007 14 : 37 44.
17. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998 27 : 1670 1677.
18. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001 8 : 237 247.
19. Stuyver LJ, Locarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001 33 : 751 757.
20. Marzano A, Gaia S, Ghisetti V et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005 11 : 402 409.
21. Marzano A, Lampertico P, Mazzaferro V et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005 11 : 532 538. (Pubitemid 40704065)
22. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993 329 : 1842 1847.
23. Zheng S, Chen Y, Liang T et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006 12 : 253 258. (Pubitemid 43273784)
24. Roche B, Feray C, Gigou M et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003 38 : 86 95.
25. Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996 24 : 1327 1333.
26. Tabor E. Infections by hepatitis B surface antigen gene mutants in Europe and North America. J Med Virol 2006 78 : S43 S47.
27. Benner KG, Lee RG, Keeffe EB et al. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology 1992 103 : 1307 1312.
28. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update. Clin Gastroenterol Hepatol 2006 4 : 936 962.
29. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 : 507 539.
30. Sherman M, Shafran S, Burak K et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol 2007 21 : 5C 24C. (Pubitemid 47162250)
31. Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003 38 : 1419 1427.
32. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004 126 : 81 90.
33. Barcena R, Del Campo S, Moraleda G et al. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. Transplantation Proc 2005 37 : 3960 3962.
34. Neff GW, Nery J, Lau DT et al. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother 2004 38 : 1999 2004.
35. Neff GW, O'Brien CB, Nery J et al. Outcomes in liver transplant recipients with hepatitis B virus: Resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004 10 : 1372 1378.
36. Konig V, Hopf U, Neuhaus P et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994 58 : 553 559. (Pubitemid 24289845)
37. McGory RW, Ishitani MB, Oliveira WM et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996 61 : 1358 1364.
38. Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991 337 : 813 815.
39. Samuel D, Bismuth A, Serres C et al. HBV infection after liver transplantation in HBsAg positive patients: Experience with long-term immunoprophylaxis. Transplantation Proc 1991 23 : 1492 1494.
40. Sawyer RG, McGory RW, Gaffey MJ et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998 227 : 841 850.
41. Steinmuller T, Seehofer D, Rayes N et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002 35 : 1528 1535. (Pubitemid 34966909)
42. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998 28 : 585 589.
43. Dumortier J, Chevallier P, Scoazec JY et al. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 2003 3 : 999 1002.
44. Han SH, Ofman J, Holt C et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000 6 : 741 748.
45. Loomba R, Rowley AK, Wesley R et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: Meta-analysis. Clin Gastroenterol Hepatol 2008 6 : 696 700.
46. Marzano A, Salizzoni M, Debernardi-Venon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001 34 : 903 910.
47. Gane EJ, Angus PW, Strasser S et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007 132 : 931 937.
48. Anselmo DM, Ghobrial RM, Jung LC et al. New era of liver transplantation for hepatitis B: A 17-year single-center experience. Ann Surg 2002 235 : 611 619 discussion 619-620.
49. Yao FY, Osorio RW, Roberts JP et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999 5 : 491 496.
50. Yan ML, Yan LN, Li B et al. Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2006 5 : 360 363.
51. Angus PW, McCaughan GW, Gane EJ et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000 6 : 429 433.
52. Naoumov NV, Lopes AR, Burra P et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001 34 : 888 894.
53. Lo CM, Liu CL, Lau GK et al. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005 11 : 807 813.
54. Angelico M, Di Paolo D, Trinito MO et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002 35 : 176 181.
55. Bienzle U, Gunther M, Neuhaus R et al. Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: Preliminary results. Liver Transpl 2002 8 : 562 564.
56. Lo CM, Liu CL, Chan SC et al. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005 43 : 283 287.
57. Sanchez-Fueyo A, Rimola A, Grande L et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000 31 : 496 501.
58. Fabrega E, Garcia-Suarez C, Guerra A et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 2003 9 : 916 920.
59. Yu AS, Vierling JM, Colquhoun SD et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001 7 : 513 517.
60. Nery JR, Nery-Avila C, Reddy KR et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003 75 : 1179 1186.
61. Dodson SF, Bonham CA, Geller DA et al. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999 68 : 1058 1061.
62. Prakoso E, Strasser SI, Koorey DJ et al. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant 2006 20 : 369 373.
63. Arslan M, Wiesner RH, Sievers C et al. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001 7 : 314 320.
64. Chalasani N, Smallwood G, Halcomb J et al. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg 1998 4 : 128 132.
65. Dominguez M, Barcena R, Garcia M et al. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 2000 6 : 440 442.
66. Horlander JC, Boyle N, Manam R et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999 318 : 304 307.
67. Loinaz C, de Juanes JR, Gonzalez EM et al. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 1997 44 : 235 238.
68. Van Thiel DH, el-Ashmawy L, Love K et al. Response to hepatitis B vaccination by liver transplant candidates. Dig Dis Sci 1992 37 : 1245 1249.
69. Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000 14 : 59B 62B.
70. McHutchison JG. Understanding hepatitis C. Am J Manag Care 2004 10 : S21 S29.
71. Davis GL, Albright JE, Cook SF et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003 9 : 331 338.
72. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002 8 : S14 S18.
73. Berenguer M, Prieto M, Rayon JM et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000 32 : 852 858.
74. Firpi RJ, Abdelmalek MF, Soldevila-Pico C et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004 10 : 1240 1247.
75. Saab S, Niho H, Comulada S et al. Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. Liver Int 2005 25 : 940 945.
76. Brown RS. Hepatitis C and liver transplantation. Nature 2005 436 : 973 978.
77. Forman LM, Lewis JD, Berlin JA et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002 122 : 889 896.
78. Watt KD, Lyden ER, McCashland TM. Poor survival after liver retransplantation: Is hepatitis C to blame? Liver Transpl 2003 9 : 1019 1024.
79. Doyle HR, Morelli F, McMichael J et al. Hepatic Retransplantation-an analysis of risk factors associated with outcome. Transplantation 1996 61 : 1499 1505.
80. Ghobrial RM, Gornbein J, Steadman R et al. Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg 2002 236 : 315 322 discussion 322-23.
81. Markmann JF, Markowitz JS, Yersiz H et al. Long-term survival after retransplantation of the liver. Ann Surg 1997 226 : 408 418 discussion 418-420.
82. McCashland T, Watt K, Lyden E et al. Retransplantation for hepatitis C: Results of a U.S. multicenter retransplant study. Liver Transpl 2007 13 : 1246 1253.
83. Neff GW, O'Brien CB, Nery J et al. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl 2004 10 : 1497 1503.
84. Pelletier SJ, Schaubel DE, Punch JD et al. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl 2005 11 : 434 440.
85. Rosen HR, Prieto M, Casanovas-Taltavull T et al. Validation and refinement of survival models for liver retransplantation. Hepatology 2003 38 : 460 469.
86. Watt KD, Menke T, Lyden E et al. Mortality while awaiting liver retransplantation: Predictability of MELD scores. Transplantation proceedings 2005 37 : 2172 2173.
87. Yao FY, Saab S, Bass NM et al. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology 2004 39 : 230 238.
88. Berenguer M, Prieto M, Cordoba J et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection. J Hepatol 1998 28 : 756 763.
89. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999 5 : S107 S114.
90. Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998 28 : 823 830.
91. Nelson DR, Soldevila-Pico C, Reed A et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001 7 : 1064 1070.
92. Neumann UP, Berg T, Bahra M et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004 41 : 830 836.
93. Rosen HR, Shackleton CR, Higa L et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997 92 : 1453 1457.
94. Sheiner PA, Schwartz ME, Mor E et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995 21 : 30 34.
95. Watt KD, Lyden ER, Gulizia JM et al. Recurrent hepatitis C posttransplant: Early preservation injury may predict poor outcome. Liver Transpl 2006 12 : 134 139.
96. Rosen HR, Chou S, Corless CL et al. Cytomegalovirus viremia: Risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997 64 : 721 726.
97. De Ruvo N, Cucchetti A, Lauro A et al. Preliminary results of a proper tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation 2005 80 : 8 12. (Pubitemid 40980888)
98. Eason JD, Nair S, Cohen AJ et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003 75 : 1396 1399.
99. Nair S, Loss GE, Cohen AJ et al. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: Impact on recurrent hepatitis C virus infection. Transplantation 2006 81 : 620 622.
100. Klintmalm GFC, Jennings L et al. Hepatitis C-3 study: Does immunosuppression affect the progression of fibrosis of HCV recurrence after liver transplantation. Hepatology 2007 46 : Abstract 7.
101. Belli LS, Burra P, Poli F et al. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 2006 130 : 695 702.
102. Ben-Ari Z, Tambur AR, Pappo O et al. Platelet-derived growth factor gene polymorphism in recurrent hepatitis C infection after liver transplantation. Transplantation 2006 81 : 392 397. (Pubitemid 43255725)
103. Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000 32 : 673 684.
104. Charlton M, Ruppert K, Belle SH et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: Results of the NIDDK liver transplantation database. Liver Transpl 2004 10 : 1120 1130.
105. Burak KW, Kremers WK, Batts KP et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002 8 : 362 369.
106. Zervos XA, Weppler D, Fragulidis GP et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998 65 : 1044 1046. (Pubitemid 28208421)
107. Martin P, Busuttil RW, Goldstein RM et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: A prospective, randomized trial. Liver Transpl 2004 10 : 1258 1262.
108. Levy G, Villamil F, Samuel D et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004 77 : 1632 1638.
109. Ghobrial RM, Steadman R, Gornbein J et al. A 10-year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients. Ann Surg 2001 234 : 384 393 discussion 393-394.
110. Fisher RA, Stone JJ, Wolfe LG et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004 18 : 463 472.
111. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007 13 : 21 29.
112. Berenguer M, Aguilera V, Prieto M et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006 12 : 762 767.
113. Zekry A, Gleeson M, Guney S et al. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 2004 10 : 52 57.
114. Wiesner R, Rabkin J, Klintmalm G et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001 7 : 442 450.
115. Jain A, Kashyap R, Demetris AJ et al. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002 8 : 40 46.
116. Bahra M, Neumann UI, Jacob D et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: Impact on histological course. Am J Transplant 2005 5 : 406 411.
117. Filipponi F, Callea F, Salizzoni M et al. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004 78 : 1488 1495.
118. Belli LS, Alberti AB, Vangeli M et al. Tapering off steroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence. Liver Transpl 2003 9 : 201 202.
119. Llado L, Xiol X, Figueras J et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: Results from a prospective multicenter randomized study. J Hepatol 2006 44 : 710 716.
120. Berenguer M, Aguilera V, Prieto M et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006 44 : 717 722.
121. Brillanti S, Vivarelli M, De Ruvo N et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002 8 : 884 888.
122. Gaglio PJ, Malireddy S, Levitt BS et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003 9 : 1028 1035.
123. Garcia-Retortillo M, Forns X, Llovet JM et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004 40 : 699 707.
124. Guo L, Orrego M, Rodriguez-Luna H et al. Living donor liver transplantation for hepatitis C-related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl 2006 12 : 560 565.
125. Olthoff KM, Merion RM, Ghobrial RM et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients: A report from the A2ALL Consortium. Ann Surg 2005 242 : 314 323, discussion 323-315.
126. Russo MW, Galanko J, Beavers K et al. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004 10 : 340 346.
127. Schiano TD, Gutierrez JA, Walewski JL et al. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 2005 42 : 1420 1428.
128. Shiffman ML, Stravitz RT, Contos MJ et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004 10 : 1248 1255.
129. Takada Y, Haga H, ITo T et al. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients. Transplantation 2006 81 : 350 354.
130. Terrault NA, Shiffman ML, Lok AS et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007 13 : 122 129.
131. Wilson SMR, Tector AJ et al. Use of infected liver donors in liver transplantation: a case-control study. Gastroenterology 2007 132 : A728.
132. Skripenova S, Trainer TD, Krawitt EL et al. Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C. J Clin Pathol 2007 60 : 321 324.
133. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003 9 : S1 S9.
134. Blasco A, Forns X, Carrion JA et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006 43 : 492 499.
135. Samonakis DN, Cholongitas E, Thalheimer U et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl 2007 13 : 1305 1311.
136. Carrion JA, Navasa M, Garcia-Retortillo M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology 2007 132 : 1746 1756.
137. Kalambokis G, Manousou P, Samonakis D et al. Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl Int 2009 22 : 172 181.
138. Carrion JA, Navasa M, Bosch J et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006 12 : 1791 1798.
139. Benlloch S, Berenguer M, Prieto M et al. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. Liver Transpl 2005 11 : 456 462.
140. Piscaglia F, Cucchetti A, Benlloch S et al. Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors. Eur J Gastroenterol Hepatol 2006 18 : 1255 1261.
141. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
142. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001 358 : 958 965.
143. Crippin JS, McCashland T, Terrault N et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002 8 : 350 355.
144. Everson GT, Trotter J, Forman L et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005 42 : 255 262.
145. Forns X, Garcia-Retortillo M, Serrano T et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003 39 : 389 396.
146. Chalasani N, Manzarbeitia C, Ferenci P et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005 41 : 289 298. (Pubitemid 40165372)
147. Angelico M, Petrolati A, Lionetti R et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007 46 : 1009 1017.
148. Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005 19 : 359 365.
149. Beckebaum S, Cicinnati VR, Zhang X et al. Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: Preliminary results of an open prospective study. Transplantation Proc 2004 36 : 1489 1491.
150. Berenguer M, Palau A, Fernandez A et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006 12 : 1067 1076.
151. Castells L, Vargas V, Allende H et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005 43 : 53 59.
152. Dumortier J, Scoazec JY, Chevallier P et al. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004 40 : 669 674.
153. Gane EJ, Lo SK, Riordan SM et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998 27 : 1403 1407.
154. Moreno Planas JM, Rubio Gonzalez E, Boullosa Grana E et al. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplantation Proc 2005 37 : 2207 2208.
155. Mukherjee S, Rogge J, Weaver L et al. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplantation proceedings 2003 35 : 3042 3044. (Pubitemid 38102126)
156. Neff GW, Montalbano M, O'Brien CB et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004 78 : 1303 1307.
157. Rodriguez-Luna H, Khatib A, Sharma P et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004 77 : 190 194.
158. Ross AS, Bhan AK, Pascual M et al. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004 18 : 166 173.
159. Sharma P, Marrero JA, Fontana RJ et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007 13 : 1100 1108.
160. Toniutto P, Fabris C, Fumo E et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005 20 : 577 582.
161. Wang CS, Ko HH, Yoshida EM et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006 6 : 1586 1599.
162. Feray C, Samuel D, Gigou M et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology 1995 22 : 1084 1089.
163. Kuo A, Tan V, Lan B et al. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl 2008 14 : 1491 1497.
164. Sheiner PA, Boros P, Klion FM et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998 28 : 831 838.
165. Shergill AK, Khalili M, Straley S et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005 5 : 118 124.
166. Davis GL, Nelson DR, Terrault N et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005 11 : 941 949.
167. Vandelli C, Renzo F, Romano L et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: Results of a 10-year prospective follow-up study. Am J Gastroenterol 2004 99 : 855 859.
168. Sanchez-Quijano A, Rey C, Aguado I et al. Hepatitis C virus infection in sexually promiscuous groups. Eur J Clin Microbiol Infect Dis 1990 9 : 610 612.
169. Tahan V, Karaca C, Yildirim B et al. Sexual transmission of HCV between spouses. Am J Gastroenterol 2005 100 : 821 824.
170. Burdick RA, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2003 63 : 2222 2229.
171. Kondili LA, Genovese D, Argentini C et al. Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. Eur J Clin Microbiol Infect Dis 2006 25 : 527 531.
172. Wedemeyer H, Pethig K, Wagner D et al. Long-term outcome of chronic hepatitis B in heart transplant recipients. Transplantation 1998 66 : 1347 1353.
173. Lezaic V, Stosovic M, Marinkovic J et al. Hepatitis B and hepatitis C virus infection and outcome of hemodialysis and kidney transplant patients. Renal failure 2008 30 : 81 87.
174. Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology Baltimore, Md 1999 29 : 257 263.
175. Kletzmayr J, Watschinger B. Chronic hepatitis B virus infection in renal transplant recipients. Semin Nephrol 2002 22 : 375 389.
176. Lunel F, Cadranel JF, Rosenheim M et al. Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology 2000 119 : 1064 1074.
177. Park SK, Yang WS, Lee YS et al. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrol Dial Transplant 2001 16 : 2222 2228.
178. Ko WJ, Chou NK, Hsu RB et al. Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area. J Heart Lung Transplant 2001 20 : 865 875.
179. Potthoff A, Tillmann HL, Bara C et al. Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. J Viral Hep 2006 13 : 734 741.
180. Ahn HJ, Kim MS, Kim YS et al. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen. J Med Virol 2007 79 : 1655 1663.
181. Knoll A, Pietrzyk M, Loss M et al. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: Low risk of HBV reactivation. Transplantation 2005 79 : 1631 1633.
182. Blanpain C, Knoop C, Delforge ML et al. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: Report on three cases and review of the literature. Transplantation 1998 66 : 883 886.
183. Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001 1 : 185 191.
184. Chan PC, Lok AS, Cheng IK et al. The impact of donor and recipient hepatitis B surface antigen status on liver disease and survival in renal transplant recipients. Transplantation 1992 53 : 128 131.
185. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): A review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003 63 : 1021 1051.
186. DaRoza G, Loewen A, Djurdjev O et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: Earlier is better. Am J Kidney Dis 2003 42 : 1184 1192.
187. Foster WQ, Murphy A, Vega DJ et al. Hepatitis B vaccination in heart transplant candidates. J Heart Lung Transplant 2006 25 : 106 109.
188. Hayney MS, Welter DL, Reynolds AM et al. High-dose hepatitis B vaccine in patients waiting for lung transplantation. Pharmacotherapy 2003 23 : 555 560.
189. Katz LH, Fraser A, Gafter-Gvili A et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: Systematic review and meta-analysis. J Viral Hep 2008 15 : 89 102.
190. Finelli L, Miller JT, Tokars JI et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Analysis 2005 18 : 52 61.
191. Gasink LB, Blumberg EA, Localio AR et al. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. Jama 2006 296 : 1843 1850.
192. Cotler SJ, Jensen DM, Kesten S. Hepatitis C virus infection and lung transplantation: A survey of practices. J Heart Lung Transplant 1999 18 : 456 459.
193. Zylberberg H, Nalpas B, Carnot F et al. Severe evolution of chronic hepatitis C in renal transplantation: A case control study. Nephrol Dial Transplant 2002 17 : 129 133.
194. Kokado Y, Takahara S, Ichimaru N et al. Clinical outcome of HCV infection after renal transplantation. Transplantation Proc 2000 32 : 1940 1943.
195. Kamar N, Rostaing L, Selves J et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 2005 5 : 1704 1712.
196. Alric L, Di-Martino V, Selves J et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002 123 : 1494 1499.
197. Romero E, Galindo P, Bravo JA et al. Hepatitis C virus infection after renal transplantation. Transplantation Proc 2008 40 : 2933 2935.
198. Gonzalez-Roncero F, Gentil MA, Valdivia MA et al. Outcome of kidney transplant in chronic hepatitis C virus patients: Effect of pretransplantation interferon-alpha2b monotherapy. Transplantation Proc 2003 35 : 1745 1747.
199. Wells JT, Lucey MR, Said A. Hepatitis C in transplant recipients of solid organs, other than liver. Clin Liver Dis 2006 10 : 901 917.
200. Gretch DR. Use and interpretation of HCV diagnostic tests in the clinical setting. Clin Liver Dis 1997 1 : 543 557, vi.
201. Sandhu J, Preiksaitis JK, Campbell PM et al. Hepatitis C prevalence and risk factors in the northern Alberta dialysis population. Am J Epidemiol 1999 150 : 58 66.
202. Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000 11 : 1343 1353.
203. Doucette KE, Weinkauf J, Sumner S et al. Treatment of hepatitis C in potential lung transplant candidates. Transplantation 2007 83 : 1652 1655.
204. Rostaing L, Modesto A, Baron E et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996 74 : 512 516. (Pubitemid 26364720)
205. Weclawiack H, Kamar N, Mehrenberger M et al. Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol Dial Transplant 2008 23 : 1043 1047.
206. Carbognin SJ, Solomon NM, Yeo FE et al. Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report. Am J Transplant 2006 6 : 1746 1751.
207. Chan SE, Schwartz JM, Rosen HR. Treatment of hepatitis C in solid organ transplantation. Drugs 2004 64 : 489 498.
208. Zeman M, Campbell P, Bain VG. Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation. Can J Gastroenterol 2006 20 : 427 431.
209. Tang S, Cheng IK, Leung VK et al. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 2003 39 : 875 878.
210. Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008 48 : 1690 1699.
211. Bruchfeld A, Lindahl K, Reichard O et al. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hep 2006 13 : 316 321.
212. Bruchfeld A, Stahle L, Andersson J et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hep 2001 8 : 287 292.
213. Carriero D, Fabrizi F, Uriel AJ et al. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008 31 : 295 302.
214. Mousa DH, Abdalla AH, Al-Shoail G et al. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplantation Proc 2004 36 : 1831 1834.
215. Tan AC, Brouwer JT, Glue P et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: Results of a pilot study. Nephrol Dial Transplant 2001 16 : 193 195.
216. van Leusen R, Adang RP, de Vries RA et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2008 23 : 721 725.
217. Guideline 2: Treatment of HCV in patients with CKD. Kidney Int 2008 73 : S20 S45.
218. Kidney disease: Improving global outcomes (KDIGO). Kidney international 2008 : S1 S99.
219. Steinman TI, Becker BN, Frost AE et al. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001 71 : 1189 1204.
220. Orens JB, Estenne M, Arcasoy S et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006 25 : 745 755.
221. Pereira BJ, Wright TL, Schmid CH et al. A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet 1995 345 : 484 487.
222. Delgado J, Munoz de Bustillo E, Ibarrola C et al. Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: Is azathioprine a contributory factor? J Heart Lung Transplant 1999 18 : 607 610.
223. Delladetsima I, Psichogiou M, Sypsa V et al. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow-up study. Am J Kidney Dis 2006 47 : 309 316.
224. Abbott KC, Bucci JR, Matsumoto CS et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003 14 : 2908 2918.
225. Bucci JR, Matsumoto CS, Swanson SJ et al. Donor hepatitis C seropositivity: Clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002 13 : 2974 2982.